Galapagos is a fully-integrated biotechnology company united around a single purpose: to transform patient outcomes through the relentless pursuit of life-changing science and innovation for more years of life and quality of life for people around the world. We focus on immunology and oncology, key strategic therapeutic areas where we have developed deep scientific expertise and a robust discovery-through-Phase 4 portfolio of drug candidates and capability in multiple drug modalities, including small molecules and cell therapies. Through collaboration, we aim to add new capabilities, technologies and product candidates with the potential to change treatment paradigms.